Atsuta Yuya, Doki Noriko
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Rinsho Ketsueki. 2021;62(2):106-114. doi: 10.11406/rinketsu.62.106.
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide and was classified as a pandemic by the World Health Organization in March 2020. However, its clinical manifestations and optimal management in immunosuppressed patients, including recipients of hematopoietic stem cell transplantation (HSCT), are unknown. There have been some international guidelines for the management of COVID-19 in HSCT recipients. In this issue, we describe the Japanese real-world clinical condition and careful points, explaining those international guidelines.
2019年冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，已在全球范围内传播，并于2020年3月被世界卫生组织列为大流行病。然而，其在免疫抑制患者中的临床表现和最佳管理方法尚不清楚，这些患者包括造血干细胞移植（HSCT）受者。目前已有一些关于HSCT受者COVID-19管理的国际指南。在本期中，我们描述了日本的实际临床情况和注意要点，并对这些国际指南进行了解释。
